Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (January 2017)
23 slides from Senseonics's investor presentation, Jan 9, 2017
Slide 1: Forward-looking statements
F69>)9,-L66215/ %;);-4-5;: )30>0 >?,?0809?> 49A:7A0 69:B9 ,9/ @969:B9 =4>6>, @9.0=?,49?40> ,9/ :?30= 1,.?:=> ?3,? 8,D .,@>0 :@= ,.?@,7 =0>@7?>, 70A07> :1 ,.?4A4?D, ;0=1:=8,9.0 := ,.340A0809?> ?: -0 8,?0=4,77D /4110=09? 1=:8 ?30 491:=8,?4:9 0C;=0>>0/ := 48;740/ -D ?30>0 1:=B,=/-7::6492 >?,?0809?>. A7
Slide 2: Mission: develop and commercialize transformative glucose monitoring products
+65.1,-5;3@ 31=-31.->1;0 -):-develop and commercialize transformative glucose monitoring products. 3
Slide 3: CGM market growth and penetration
&0-M)92-; l: #<1+23@ G96>15/ CGM .):;-:; /96>15/ :-/4-5; $8 10 $6.5 $7 $5.8 8 $6 $5 6 E<967-$3.5 $4 $3.3 E<967-4 $2.5 $3 $2 2 $0.7 $1 2020 E:;. 2020 E:;. 2020 E:;. 2015 2015 2015 '.%. '.%. 0 $0 CGM* %-' - 0 CAG l5:<315 "<47: %-0 CAG %MBG %-(0 CAG 2015 2020 n ens "e $ Managed Pop! a on Type 1 CGM pen
Slide 4: Eversense CGM System
l5;96,<+15/ ;0-H1/03@ D1..-9-5;1);-, CGM %@:;-4 E"ersense s he AM s$s em # h he & !. 7);1-5;: :)@ ;0-@ >6<3, <:-1; -=-9@,)@ ;6 4)5)/-;0-19 ,1)*-;-: 88% 5
Slide 5: Eversense System: sensor, smart transmitter, mobile app
&0-E=-9:-5:-%@:;-4 %-5:69 %4)9; &9)5:41;;-9 M6*13-A77 Sensor that lasts up to 180 days No weekly sensor insertion No open wound Removable and rechargeable On-body vibe alerts Gentle-on-skin adhesive No extra device to carry iOS and Android platform Alarm settings & reports 6
Slide 6: Eversense proven sensor technology
E:;)*31:0-,, "96=-5 %-5:69 &-+05636/@ B16+647);1*3-E5+):-4-5; !7;1+)3 l5;-9.)+-#:9-09ED8,?4., 17@:=0>.09.0 -,>0/ 80,>@=0809? "63@4-9 H@,96/-3 (48;70 49-:114.0 ;=:.0/@=0 G 70>> ?3,9 5 849> FC A5;-55) no weekly sensor insertion B0>?-49-.7,>> ,..@=,.D no open wund !,>?> @; ?: 180-/,D> B4?3:@? =08:A492
Slide 7: On-body alerts for extra security
onbodyalerts forextra security 8
Slide 8: Eversense mobile app features
E=-9:-5:-M6*13-"3);.694 E5)*3-: A,=)5+-, F-);<9-: "9-,1+;1=-L6>/H1/0 G3<+6:-A3-9;: & $);-6. C0)5/-A3-9;: $-46;-M651;6915/ $-769;: D19-+;3@ 65 A77 >1;0 E=-9:-5:-6> $-),15/: 65 A773->);+0 Email PDF report to caregiver 9
Slide 9: Industry leading accuracy
industry leading accuracy '.%. "$ECl%E ll %;<,@ C6473-;-, Determine safety and accuracy accurate "A'D 8.8% G7@.:>0 =,920 :1 40-400 82//! )3=:@23:@? 90-/,D @>0 safe #: I910.?4:9> #: ,/30>4A0 =0,.?4:9> Long life 94% :1 >@-50.?> ?3=@ 90 /,D> :1 .:9?49@:@> @>0 73% :1 >@-50.?> ;=:50.?0/ ?3=@180 /,D> :1 .
Slide 10: Sensor performance comparison
%-5:69 "-9.694)5+-C647)91:65 Percent of System Readings Within Matched Pairs MARD (%) 15/15% :1 '010=09.0 20/20% :1 '010=09.0 30/30% :1 '010=09.0 40/40% :1 '010=09.0 Device EA0=>09>0 16,653 86% 93% 98% 99% 8.8 D0C.:8 G5* 2,263 86% 93% 98% 99% 9.0 12,323 / 12,080 !4-=0 %=:* 72% 84% 95% 99% 12.1 "0/?=
Slide 11: Declaration of sensor user convenience
$-,<+-C)31*9);165 %-5:69 user convenience 2-Cal Sensor, MARD 8.8% 1-Cal Sensor, MARD 9.5% 400 400 same sensor 350 350 L)* $-.-9-5+-300 300 250 250 E=-9:-5:-G3<+6:-$-),15/: 200 200 150 150 %MBG 100 100 &)9/-; $)5/-50 50 0 0 22:00 22:00 02:00 06:00 10:00 14:00 18:00 02:00 06:00 10:00 14:00 18:00 EA0=>
Slide 12: Patient testimonials
");1-5; “I learned a lot about my diabetes and how to manage lows and highs, when to eat and when to take more insulin or turn off the insulin pump.” G )D;0 1 ;,?409?, (B0/09 “Significant reduction of hypoglycemia due to early warning safety gain quality I have exercised much more.” G )D;0 1 ;,?409?
Slide 13: Physician feedback
"0@:1+1)5 F--,*)+2 “One of the features of endocrinology that appealed to me is the relative absence of procedures. After performing the sensor insertion, I realized that I no longer fear procedures. I felt very comfortable after the first two sensors.” D9. M)92 C091:;-5:-5, D4,-7: C7494.,7 '0>0,=.3
Slide 14: Strategic positioning for market acceptance
%;9);-/1+ "6:1;16515/ F69 M)?14<4 A++-7;)5+-leverage channels competitive price to healthcare system *?474E0 0C;0=409.0/ /4>?=4-@?:=> $*( B@47/ /4=0.? >,70> 1:=.0 49 *( ),=20? 60D .7494. ,9/ ;,?409? -,>0 ):?,7 ;=4.0 =0170.?> =048-@=>0809? ?: 09/:> '0/@.0/ .:-;,D> B4?3 -4-,99@,7 >09>:= ;@=.3,>0 '0/@.
Slide 15: Commercialization: European launch
Launch in 2017 European country expansion in 2017 and beyond C644-9+1)31A);165 %;9);-/@ Focused on addressable CGM markets 16
Slide 16: Sales approach: build commercial infrastructure
'% %)3-: A7796)+0 %)3-: F69+-$63-B@ A+;1=1;@ )5, %-/4-5; build commercial infrastructure to drive revenue B-/15 :)3-: 4)5)/-4-5; )5, 4)5)/-, +)9-:)3-: )++6<5; 01915/ 41,-2017 &9)1515/ F6+<: 65 ;)9/-;-, 01/0-15:<315 79-:+91*15/ +3151+: "96=1,-+3151+ ;9)1515/ )5, 9-14*<9:-4-5; +3)14: :<7769; Activitie
Slide 17: Product pipeline
"96,<+; "17-315-"96,<+;: ;6 /96> 4)92-; :0)9-"96,<+;: ;6 *96),-5 ;)9/-; 4)92-; On-Demand MDl ");1-5;: "<47 ");1-5;: 65-MDl ");1-5;: !AD ");1-5;: 19 I9?09>4A07D ",9,20/ %,?409?> I9>@749 *>492 %,?409?> ,9/ )D;0 2 %,?409?> Eversense 180 full 180 day with dosing claim, 1x/Day calibration Eversense for P
Slide 18: Long-term flash glucose monitoring with no transmitter
the long-term flash glucose !5-D-4)5, monitoring with no transmitter Implanted 180 day sensor, smartphone app, no transmitter worn Direct sensor communication with NFC-interfaced smartphone NFC-interfaced phones act as transmitter and receiver; powers and reads implanted sensor 20
Slide 19: Gemini: the ultimate flexibility
/ Gemini the ultimate flexibility for your daily life
Slide 20: Key financial metrics
K-@ F15)5+1)3 M-;91+: 2016 Preliminary Results 2017 Guidance C):0/C):0 E8<1=)3-5;: B$20M $-=-5<-B$0.3M 6.0 C 7.0M in revenue D-*; $20M %0)9-: !<;:;)5,15/ B93.4M 22
Slide 21: 2017 milestones
%-5:-651+: 2017 M13-:;65-: 1H L)<5+0 G-5 2 &9)5:41;;-9 15 E' 1H CE M)92 A7796=)3 180 D)@ 2H lDE 180 D)@ &91)3 2H "MA A7796=)3 2H '.%. L)<5+0 F( E?7)5, E' C644-9+1)3 L)<5+0 EA0=>09>0 CG" (D>?08 4> CE 8,=60/ ,9/ ,;;=:A0/ 1:= >,70 49 E@=:;0. EA0=>09>0 CG" (D>?08 4> ,9 I9A0>?42,?4:9,7 D0A4.0 ,9/ 4> 7484
Slide 22: January 2017 Investor Presentation
J)5<)9@ 2017 l5=-:;69 "9-:-5;);165 .:914/09?7D 74A0 7410 B4?3 0,>0 24
Slide 23: Senseonics
vi -. Senseonics. aks Investor Presentation igs confidently live life with ease
Senseonics Holdings — Investor Presentation (January 2017) on 6ix